1
|
Makdissi S, Parsons BD, Di Cara F. Towards early detection of neurodegenerative diseases: A gut feeling. Front Cell Dev Biol 2023; 11:1087091. [PMID: 36824371 PMCID: PMC9941184 DOI: 10.3389/fcell.2023.1087091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 01/20/2023] [Indexed: 02/10/2023] Open
Abstract
The gastrointestinal tract communicates with the nervous system through a bidirectional network of signaling pathways called the gut-brain axis, which consists of multiple connections, including the enteric nervous system, the vagus nerve, the immune system, endocrine signals, the microbiota, and its metabolites. Alteration of communications in the gut-brain axis is emerging as an overlooked cause of neuroinflammation. Neuroinflammation is a common feature of the pathogenic mechanisms involved in various neurodegenerative diseases (NDs) that are incurable and debilitating conditions resulting in progressive degeneration and death of neurons, such as in Alzheimer and Parkinson diseases. NDs are a leading cause of global death and disability, and the incidences are expected to increase in the following decades if prevention strategies and successful treatment remain elusive. To date, the etiology of NDs is unclear due to the complexity of the mechanisms of diseases involving genetic and environmental factors, including diet and microbiota. Emerging evidence suggests that changes in diet, alteration of the microbiota, and deregulation of metabolism in the intestinal epithelium influence the inflammatory status of the neurons linked to disease insurgence and progression. This review will describe the leading players of the so-called diet-microbiota-gut-brain (DMGB) axis in the context of NDs. We will report recent findings from studies in model organisms such as rodents and fruit flies that support the role of diets, commensals, and intestinal epithelial functions as an overlooked primary regulator of brain health. We will finish discussing the pivotal role of metabolisms of cellular organelles such as mitochondria and peroxisomes in maintaining the DMGB axis and how alteration of the latter can be used as early disease makers and novel therapeutic targets.
Collapse
Affiliation(s)
- Stephanie Makdissi
- Dalhousie University, Department of Microbiology and Immunology, Halifax, NS, Canada
- IWK Health Centre, Department of Pediatrics, Halifax, Canada
| | - Brendon D. Parsons
- Dalhousie University, Department of Microbiology and Immunology, Halifax, NS, Canada
| | - Francesca Di Cara
- Dalhousie University, Department of Microbiology and Immunology, Halifax, NS, Canada
- IWK Health Centre, Department of Pediatrics, Halifax, Canada
| |
Collapse
|
2
|
Forrest SL, Tartaglia MC, Kim A, Alcaide-Leon P, Rogaeva E, Lang A, Kovacs GG. Progressive Supranuclear Palsy Syndrome Associated With a Novel Tauopathy: Case Study. Neurology 2022; 99:1094-1098. [PMID: 36192179 DOI: 10.1212/wnl.0000000000201485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Accepted: 09/13/2022] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND AND OBJECTIVES To report a novel tauopathy in a patient with protracted course progressive supranuclear palsy (PC-PSP). METHODS This was a clinical follow-up, gene analysis, neuropathologic study. RESULTS A 73-year-old man presented with diplopia, slowness, shuffling gait, and falls. Neurologic examination revealed slowed saccades, restricted up-gaze, and mild parkinsonism. Three years after onset, he developed personality changes. Slowly progressive parkinsonism was associated with memory and executive deficits. MRI showed subtle bilateral hippocampal and midbrain tegmentum atrophy and hyperintensity in the brainstem tegmentum and white matter of the medial temporal lobe. The duration of illness was 11 years. There were no pathogenic mutations in 80 genes known to be involved in neurodegeneration, including MAPT (H1/H1 haplotype) and APOE (ε3/ε3 genotype). Neuropathology revealed PSP type pathology together with the pathology described in the novel limbic-predominant neuronal inclusion body 4-repeat tauopathy (LNT) correlating well with the signal alterations seen in MRI. DISCUSSION Our observation broadens the spectrum of tau pathology associated with PC-PSP and suggests that memory deficit and hippocampal atrophy may be suggestive of non-Alzheimer disease pathology, including LNT. Understanding the diverse range of tau morphologies may help explain phenotypic heterogeneity seen in PSP.
Collapse
Affiliation(s)
- Shelley L Forrest
- From the Dementia Research Centre (S.L.F.), Macquarie Medical School, Faculty of Health and Human Sciences, Macquarie University, Sydney, Australia; Tanz Centre for Research in Neurodegenerative Disease (S.L.F., M.C.T., A.K., E.R., A.L., G.G.K.), University of Toronto, ON, Canada; University Health Network Memory Clinic & Krembil Brain Institute (M.C.T.), University Health Network, Toronto, ON, Canada; Department of Medical Imaging (P.A.-L.), University of Toronto, Ontario, Canada; Edmond J. Safra Program in Parkinson's Disease (A.L., G.G.K.), Rossy Program for PSP Research and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, ON, Canada; Department of Laboratory Medicine and Pathobiology and Department of Medicine (G.G.K.), University of Toronto, ON, Canada; and Laboratory Medicine Program & Krembil Brain Institute (G.G.K.), University Health Network, ON, Canada
| | - Maria Carmela Tartaglia
- From the Dementia Research Centre (S.L.F.), Macquarie Medical School, Faculty of Health and Human Sciences, Macquarie University, Sydney, Australia; Tanz Centre for Research in Neurodegenerative Disease (S.L.F., M.C.T., A.K., E.R., A.L., G.G.K.), University of Toronto, ON, Canada; University Health Network Memory Clinic & Krembil Brain Institute (M.C.T.), University Health Network, Toronto, ON, Canada; Department of Medical Imaging (P.A.-L.), University of Toronto, Ontario, Canada; Edmond J. Safra Program in Parkinson's Disease (A.L., G.G.K.), Rossy Program for PSP Research and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, ON, Canada; Department of Laboratory Medicine and Pathobiology and Department of Medicine (G.G.K.), University of Toronto, ON, Canada; and Laboratory Medicine Program & Krembil Brain Institute (G.G.K.), University Health Network, ON, Canada
| | - Ain Kim
- From the Dementia Research Centre (S.L.F.), Macquarie Medical School, Faculty of Health and Human Sciences, Macquarie University, Sydney, Australia; Tanz Centre for Research in Neurodegenerative Disease (S.L.F., M.C.T., A.K., E.R., A.L., G.G.K.), University of Toronto, ON, Canada; University Health Network Memory Clinic & Krembil Brain Institute (M.C.T.), University Health Network, Toronto, ON, Canada; Department of Medical Imaging (P.A.-L.), University of Toronto, Ontario, Canada; Edmond J. Safra Program in Parkinson's Disease (A.L., G.G.K.), Rossy Program for PSP Research and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, ON, Canada; Department of Laboratory Medicine and Pathobiology and Department of Medicine (G.G.K.), University of Toronto, ON, Canada; and Laboratory Medicine Program & Krembil Brain Institute (G.G.K.), University Health Network, ON, Canada
| | - Paula Alcaide-Leon
- From the Dementia Research Centre (S.L.F.), Macquarie Medical School, Faculty of Health and Human Sciences, Macquarie University, Sydney, Australia; Tanz Centre for Research in Neurodegenerative Disease (S.L.F., M.C.T., A.K., E.R., A.L., G.G.K.), University of Toronto, ON, Canada; University Health Network Memory Clinic & Krembil Brain Institute (M.C.T.), University Health Network, Toronto, ON, Canada; Department of Medical Imaging (P.A.-L.), University of Toronto, Ontario, Canada; Edmond J. Safra Program in Parkinson's Disease (A.L., G.G.K.), Rossy Program for PSP Research and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, ON, Canada; Department of Laboratory Medicine and Pathobiology and Department of Medicine (G.G.K.), University of Toronto, ON, Canada; and Laboratory Medicine Program & Krembil Brain Institute (G.G.K.), University Health Network, ON, Canada
| | - Ekaterina Rogaeva
- From the Dementia Research Centre (S.L.F.), Macquarie Medical School, Faculty of Health and Human Sciences, Macquarie University, Sydney, Australia; Tanz Centre for Research in Neurodegenerative Disease (S.L.F., M.C.T., A.K., E.R., A.L., G.G.K.), University of Toronto, ON, Canada; University Health Network Memory Clinic & Krembil Brain Institute (M.C.T.), University Health Network, Toronto, ON, Canada; Department of Medical Imaging (P.A.-L.), University of Toronto, Ontario, Canada; Edmond J. Safra Program in Parkinson's Disease (A.L., G.G.K.), Rossy Program for PSP Research and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, ON, Canada; Department of Laboratory Medicine and Pathobiology and Department of Medicine (G.G.K.), University of Toronto, ON, Canada; and Laboratory Medicine Program & Krembil Brain Institute (G.G.K.), University Health Network, ON, Canada
| | - Anthony Lang
- From the Dementia Research Centre (S.L.F.), Macquarie Medical School, Faculty of Health and Human Sciences, Macquarie University, Sydney, Australia; Tanz Centre for Research in Neurodegenerative Disease (S.L.F., M.C.T., A.K., E.R., A.L., G.G.K.), University of Toronto, ON, Canada; University Health Network Memory Clinic & Krembil Brain Institute (M.C.T.), University Health Network, Toronto, ON, Canada; Department of Medical Imaging (P.A.-L.), University of Toronto, Ontario, Canada; Edmond J. Safra Program in Parkinson's Disease (A.L., G.G.K.), Rossy Program for PSP Research and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, ON, Canada; Department of Laboratory Medicine and Pathobiology and Department of Medicine (G.G.K.), University of Toronto, ON, Canada; and Laboratory Medicine Program & Krembil Brain Institute (G.G.K.), University Health Network, ON, Canada
| | - Gabor G Kovacs
- From the Dementia Research Centre (S.L.F.), Macquarie Medical School, Faculty of Health and Human Sciences, Macquarie University, Sydney, Australia; Tanz Centre for Research in Neurodegenerative Disease (S.L.F., M.C.T., A.K., E.R., A.L., G.G.K.), University of Toronto, ON, Canada; University Health Network Memory Clinic & Krembil Brain Institute (M.C.T.), University Health Network, Toronto, ON, Canada; Department of Medical Imaging (P.A.-L.), University of Toronto, Ontario, Canada; Edmond J. Safra Program in Parkinson's Disease (A.L., G.G.K.), Rossy Program for PSP Research and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, ON, Canada; Department of Laboratory Medicine and Pathobiology and Department of Medicine (G.G.K.), University of Toronto, ON, Canada; and Laboratory Medicine Program & Krembil Brain Institute (G.G.K.), University Health Network, ON, Canada.
| |
Collapse
|
3
|
Kovacs GG, Ghetti B, Goedert M. Classification of Diseases with Accumulation of Tau Protein. Neuropathol Appl Neurobiol 2022; 48:e12792. [PMID: 35064600 PMCID: PMC9352145 DOI: 10.1111/nan.12792] [Citation(s) in RCA: 30] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Accepted: 01/07/2022] [Indexed: 11/28/2022]
Affiliation(s)
- Gabor G Kovacs
- Tanz Centre for Research in Neurodegenerative Disease and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.,Laboratory Medicine Program & Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada
| | - Bernardino Ghetti
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indiana, USA
| | - Michel Goedert
- MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, UK
| |
Collapse
|
4
|
Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, van Beers M, Tarutani A, Kametani F, Garringer HJ, Vidal R, Hallinan GI, Lashley T, Saito Y, Murayama S, Yoshida M, Tanaka H, Kakita A, Ikeuchi T, Robinson AC, Mann DMA, Kovacs GG, Revesz T, Ghetti B, Hasegawa M, Goedert M, Scheres SHW. Structure-based classification of tauopathies. Nature 2021; 598:359-363. [PMID: 34588692 DOI: 10.1038/s41586-021-03911-7] [Citation(s) in RCA: 359] [Impact Index Per Article: 119.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Accepted: 08/13/2021] [Indexed: 11/09/2022]
Abstract
The ordered assembly of tau protein into filaments characterizes several neurodegenerative diseases, which are called tauopathies. It was previously reported that, by cryo-electron microscopy, the structures of tau filaments from Alzheimer's disease1,2, Pick's disease3, chronic traumatic encephalopathy4 and corticobasal degeneration5 are distinct. Here we show that the structures of tau filaments from progressive supranuclear palsy (PSP) define a new three-layered fold. Moreover, the structures of tau filaments from globular glial tauopathy are similar to those from PSP. The tau filament fold of argyrophilic grain disease (AGD) differs, instead resembling the four-layered fold of corticobasal degeneration. The AGD fold is also observed in ageing-related tau astrogliopathy. Tau protofilament structures from inherited cases of mutations at positions +3 or +16 in intron 10 of MAPT (the microtubule-associated protein tau gene) are also identical to those from AGD, suggesting that relative overproduction of four-repeat tau can give rise to the AGD fold. Finally, the structures of tau filaments from cases of familial British dementia and familial Danish dementia are the same as those from cases of Alzheimer's disease and primary age-related tauopathy. These findings suggest a hierarchical classification of tauopathies on the basis of their filament folds, which complements clinical diagnosis and neuropathology and also allows the identification of new entities-as we show for a case diagnosed as PSP, but with filament structures that are intermediate between those of globular glial tauopathy and PSP.
Collapse
Affiliation(s)
- Yang Shi
- MRC Laboratory of Molecular Biology, Cambridge, UK
| | | | - Yang Yang
- MRC Laboratory of Molecular Biology, Cambridge, UK
| | | | | | - Abhay Kotecha
- Thermo Fisher Scientific, Eindhoven, The Netherlands
| | | | - Airi Tarutani
- Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Fuyuki Kametani
- Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Holly J Garringer
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Ruben Vidal
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Grace I Hallinan
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Tammaryn Lashley
- Department of Neurodegenerative Disease and Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, UK
| | - Yuko Saito
- Department of Neuropathology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan
| | - Shigeo Murayama
- Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, University of Osaka, Osaka, Japan
| | - Mari Yoshida
- Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Japan
| | - Hidetomo Tanaka
- Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan
| | - Akiyoshi Kakita
- Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan
| | - Takeshi Ikeuchi
- Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan
| | - Andrew C Robinson
- Clinical Sciences Building, University of Manchester, Salford Royal Foundation Trust, Salford, UK
| | - David M A Mann
- Clinical Sciences Building, University of Manchester, Salford Royal Foundation Trust, Salford, UK
| | - Gabor G Kovacs
- Department of Laboratory Medicine and Pathobiology and Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.,Institute of Neurology, Medical University of Vienna, Vienna, Austria
| | - Tamas Revesz
- Department of Neurodegenerative Disease and Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, UK
| | - Bernardino Ghetti
- Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Masato Hasegawa
- Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | | | | |
Collapse
|
5
|
Robinson JL, Porta S, Garrett FG, Zhang P, Xie SX, Suh E, Van Deerlin VM, Abner EL, Jicha GA, Barber JM, Lee VMY, Lee EB, Trojanowski JQ, Nelson PT. Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain 2021; 143:2844-2857. [PMID: 32830216 DOI: 10.1093/brain/awaa219] [Citation(s) in RCA: 44] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Revised: 05/01/2020] [Accepted: 05/21/2020] [Indexed: 12/12/2022] Open
Abstract
TAR-DNA binding protein-43 (TDP-43) proteinopathy is seen in multiple brain diseases. A standardized terminology was recommended recently for common age-related TDP-43 proteinopathy: limbic-predominant, age-related TDP-43 encephalopathy (LATE) and the underlying neuropathological changes, LATE-NC. LATE-NC may be co-morbid with Alzheimer's disease neuropathological changes (ADNC). However, there currently are ill-defined diagnostic classification issues among LATE-NC, ADNC, and frontotemporal lobar degeneration with TDP-43 (FTLD-TDP). A practical challenge is that different autopsy cohorts are composed of disparate groups of research volunteers: hospital- and clinic-based cohorts are enriched for FTLD-TDP cases, whereas community-based cohorts have more LATE-NC cases. Neuropathological methods also differ across laboratories. Here, we combined both cases and neuropathologists' diagnoses from two research centres-University of Pennsylvania and University of Kentucky. The study was designed to compare neuropathological findings between FTLD-TDP and pathologically severe LATE-NC. First, cases were selected from the University of Pennsylvania with pathological diagnoses of either FTLD-TDP (n = 33) or severe LATE-NC (mostly stage 3) with co-morbid ADNC (n = 30). Sections from these University of Pennsylvania cases were cut from amygdala, anterior cingulate, superior/mid-temporal, and middle frontal gyrus. These sections were stained for phospho-TDP-43 immunohistochemically and evaluated independently by two University of Kentucky neuropathologists blinded to case data. A simple set of criteria hypothesized to differentiate FTLD-TDP from LATE-NC was generated based on density of TDP-43 immunoreactive neuronal cytoplasmic inclusions in the neocortical regions. Criteria-based sensitivity and specificity of differentiating severe LATE-NC from FTLD-TDP cases with blind evaluation was ∼90%. Another proposed neuropathological feature related to TDP-43 proteinopathy in aged individuals is 'Alpha' versus 'Beta' in amygdala. Alpha and Beta status was diagnosed by neuropathologists from both universities (n = 5 raters). There was poor inter-rater reliability of Alpha/Beta classification (mean κ = 0.31). We next tested a separate cohort of cases from University of Kentucky with either FTLD-TDP (n = 8) or with relatively 'pure' severe LATE-NC (lacking intermediate or severe ADNC; n = 14). The simple criteria were applied by neuropathologists blinded to the prior diagnoses at University of Pennsylvania. Again, the criteria for differentiating LATE-NC from FTLD-TDP was effective, with sensitivity and specificity ∼90%. If more representative cases from each cohort (including less severe TDP-43 proteinopathy) had been included, the overall accuracy for identifying LATE-NC was estimated at >98% for both cohorts. Also across both cohorts, cases with FTLD-TDP died younger than those with LATE-NC (P < 0.0001). We conclude that in most cases, severe LATE-NC and FTLD-TDP can be differentiated by applying simple neuropathological criteria.
Collapse
Affiliation(s)
- John L Robinson
- Alzheimer's Disease Core Center, University of Pennsyvania, Philadelphia, PA, USA.,Center for Neurodegenerative Disease Research, University of Pennsyvania, Philadelphia, PA, USA.,Department of Pathology and Laboratory Medicine, University of Pennsyvania, Philadelphia, PA, USA
| | - Sílvia Porta
- Alzheimer's Disease Core Center, University of Pennsyvania, Philadelphia, PA, USA.,Center for Neurodegenerative Disease Research, University of Pennsyvania, Philadelphia, PA, USA.,Department of Pathology and Laboratory Medicine, University of Pennsyvania, Philadelphia, PA, USA
| | - Filip G Garrett
- Department of Pathology, University of Kentucky, Lexington, KY, USA
| | - Panpan Zhang
- Alzheimer's Disease Core Center, University of Pennsyvania, Philadelphia, PA, USA.,Department of Biostatistics, Epidemiology and Informatics, University of Pennsyvania, Philadelphia, PA, USA
| | - Sharon X Xie
- Alzheimer's Disease Core Center, University of Pennsyvania, Philadelphia, PA, USA.,Department of Biostatistics, Epidemiology and Informatics, University of Pennsyvania, Philadelphia, PA, USA
| | - EunRan Suh
- Alzheimer's Disease Core Center, University of Pennsyvania, Philadelphia, PA, USA.,Center for Neurodegenerative Disease Research, University of Pennsyvania, Philadelphia, PA, USA.,Department of Pathology and Laboratory Medicine, University of Pennsyvania, Philadelphia, PA, USA
| | - Vivianna M Van Deerlin
- Alzheimer's Disease Core Center, University of Pennsyvania, Philadelphia, PA, USA.,Center for Neurodegenerative Disease Research, University of Pennsyvania, Philadelphia, PA, USA.,Department of Pathology and Laboratory Medicine, University of Pennsyvania, Philadelphia, PA, USA
| | - Erin L Abner
- Department of Epidemiology, University of Kentucky, Lexington, KY, USA.,Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
| | - Gregory A Jicha
- Department of Neurology, University of Kentucky, Lexington, KY, USA.,Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
| | - Justin M Barber
- Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
| | - Virginia M-Y Lee
- Alzheimer's Disease Core Center, University of Pennsyvania, Philadelphia, PA, USA.,Center for Neurodegenerative Disease Research, University of Pennsyvania, Philadelphia, PA, USA.,Department of Pathology and Laboratory Medicine, University of Pennsyvania, Philadelphia, PA, USA
| | - Edward B Lee
- Alzheimer's Disease Core Center, University of Pennsyvania, Philadelphia, PA, USA.,Center for Neurodegenerative Disease Research, University of Pennsyvania, Philadelphia, PA, USA.,Department of Pathology and Laboratory Medicine, University of Pennsyvania, Philadelphia, PA, USA
| | - John Q Trojanowski
- Alzheimer's Disease Core Center, University of Pennsyvania, Philadelphia, PA, USA.,Center for Neurodegenerative Disease Research, University of Pennsyvania, Philadelphia, PA, USA.,Department of Pathology and Laboratory Medicine, University of Pennsyvania, Philadelphia, PA, USA
| | - Peter T Nelson
- Department of Pathology, University of Kentucky, Lexington, KY, USA.,Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
| |
Collapse
|
6
|
Llibre‐Guerra JJ, Lee SE, Suemoto CK, Ehrenberg AJ, Kovacs GG, Karydas A, Staffaroni A, Franca Resende EDP, Kim E, Hwang J, Ramos EM, Wojta KJ, Pasquini L, Pang SY, Spina S, Allen IE, Kramer J, Miller BL, Seeley WW, Grinberg LT. A novel temporal-predominant neuro-astroglial tauopathy associated with TMEM106B gene polymorphism in FTLD/ALS-TDP. Brain Pathol 2021; 31:267-282. [PMID: 33314436 PMCID: PMC7946775 DOI: 10.1111/bpa.12924] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2020] [Revised: 09/30/2020] [Accepted: 11/24/2020] [Indexed: 12/13/2022] Open
Abstract
Polymorphisms in TMEM106B, a gene on chromosome 7p21.3 involved in lysosomal trafficking, correlates to worse neuropathological, and clinical outcomes in frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) with TDP-43 inclusions. In a small cohort of C9orf72 expansion carriers, we previously found an atypical, neuroglial tauopathy in cases harboring a TMEM106B rs1990622 A/A genotype. To test whether TMEM106B genotype affects the risk of developing atypical tauopathy under a recessive genotype model (presence versus absence of two major alleles: A/A vs. A/G and G/G). We characterized the atypical tauopathy neuropathologically and determined its frequency by TMEM106B rs1990622 genotypes in 90 postmortem cases with a primary diagnosis of FTLD/ALS-TDP [mean age at death 65.5 years (±8.1), 40% female]. We investigated the effect of this new atypical tauopathy on demographics and clinical and neuropsychological metrics. We also genotyped TMEM106B in an independent series with phenotypically similar cases. Sixteen cases (16/90, 17.7 %) showed the temporal-predominant neuro-astroglial tauopathy, and 93.7% of them carried an A/A genotype (vs. ~35% in a population cohort). The odds ratio of FTLD/ALS-TDP individuals with the A/A genotype showing neuro-astroglial tauopathy was 13.9. Individuals with this tauopathy were older at onset (p = 0.01). The validation cohort had a similarly high proportion of rs1990622 A/A genotype. TDP-43 and tau changes co-occur in a subset of neurons. Our data add to the growing body of evidence that TMEM106B polymorphisms may modulate neurodegeneration. A distinctive medial temporal predominant, 4-repeat, neuro-astroglial tauopathy strongly correlates to TMEM106B A/A genotype in FTLD/ALS-TDP cases.
Collapse
Affiliation(s)
- Jorge J. Llibre‐Guerra
- Department of NeurologyUCSF Weill Institute for NeurosciencesUniversity of California, San Francisco, San FranciscoCAUSA,National Institute of Neurology and NeurosurgeryLa HabanaCuba,Global Brain Health InstituteUniversity of California, San FranciscoSan FranciscoCAUSA
| | - Suzee E. Lee
- Department of NeurologyUCSF Weill Institute for NeurosciencesUniversity of California, San Francisco, San FranciscoCAUSA
| | - Claudia K. Suemoto
- Biobank for Aging StudiesLIM‐22Department of PathologyUniversity of Sao Paulo Medical SchoolSao PauloBrazil,Division of GeriatricsDepartment of Clinical MedicineUniversity of Sao Paulo Medical SchoolSao PauloBrazil
| | - Alexander J. Ehrenberg
- Department of NeurologyUCSF Weill Institute for NeurosciencesUniversity of California, San Francisco, San FranciscoCAUSA,Department of Integrative BiologyUniversity of California, BerkeleyBerkeleyCAUSA
| | - Gabor G. Kovacs
- Institute of NeurologyMedical University ViennaViennaAustria,Department of Laboratory Medicine and Pathobiology and Tanz Centre for Research in Neurodegenerative DiseaseUniversity of TorontoTorontoONCanada,Laboratory Medicine Program & Krembil Brain InstituteUniversity Health NetworkTorontoONCanada
| | - Anna Karydas
- Department of NeurologyUCSF Weill Institute for NeurosciencesUniversity of California, San Francisco, San FranciscoCAUSA
| | - Adam Staffaroni
- Department of NeurologyUCSF Weill Institute for NeurosciencesUniversity of California, San Francisco, San FranciscoCAUSA
| | - Elisa De Paula Franca Resende
- Department of NeurologyUCSF Weill Institute for NeurosciencesUniversity of California, San Francisco, San FranciscoCAUSA,Global Brain Health InstituteUniversity of California, San FranciscoSan FranciscoCAUSA,Grupo de Pesquisa em Neurologia Cognitiva e do ComportamentoDepartamento de Clínica MédicaFaculdade de Medicina da Universidade Federal de Minas GeraisBelo HorizonteBrazil
| | - Eun‐Joo Kim
- Department of NeurologyPusan National University HospitalPusan National University School of Medicine and Medical Research InstituteBusanRepublic of Korea
| | - Ji‐Hye Hwang
- Department of NeurologyUCSF Weill Institute for NeurosciencesUniversity of California, San Francisco, San FranciscoCAUSA
| | - Eliana Marisa Ramos
- Department of PsychiatryDavid Geffen School of MedicineUniversity of California Los AngelesLos AngelesCAUSA
| | - Kevin J. Wojta
- Department of PsychiatryDavid Geffen School of MedicineUniversity of California Los AngelesLos AngelesCAUSA
| | - Lorenzo Pasquini
- Department of NeurologyUCSF Weill Institute for NeurosciencesUniversity of California, San Francisco, San FranciscoCAUSA
| | - Shirley Yin‐Yu Pang
- Division of NeurologyDepartment of MedicineQueen Mary HospitalThe University of Hong KongHong Kong SARChina
| | - Salvatore Spina
- Department of NeurologyUCSF Weill Institute for NeurosciencesUniversity of California, San Francisco, San FranciscoCAUSA
| | - Isabel E. Allen
- Global Brain Health InstituteUniversity of California, San FranciscoSan FranciscoCAUSA,Department of Epidemiology & BiostatisticsUniversity of California, San FranciscoSan FranciscoCAUSA
| | - Joel Kramer
- Department of NeurologyUCSF Weill Institute for NeurosciencesUniversity of California, San Francisco, San FranciscoCAUSA
| | - Bruce L. Miller
- Department of NeurologyUCSF Weill Institute for NeurosciencesUniversity of California, San Francisco, San FranciscoCAUSA
| | - William W. Seeley
- Department of NeurologyUCSF Weill Institute for NeurosciencesUniversity of California, San Francisco, San FranciscoCAUSA,Department of Pathology and Laboratory MedicineUniversity of California, San FranciscoSan FranciscoCAUSA
| | - Lea T. Grinberg
- Department of NeurologyUCSF Weill Institute for NeurosciencesUniversity of California, San Francisco, San FranciscoCAUSA,Global Brain Health InstituteUniversity of California, San FranciscoSan FranciscoCAUSA,Biobank for Aging StudiesLIM‐22Department of PathologyUniversity of Sao Paulo Medical SchoolSao PauloBrazil,Department of Pathology and Laboratory MedicineUniversity of California, San FranciscoSan FranciscoCAUSA
| |
Collapse
|
7
|
Ferrer I. Oligodendrogliopathy in neurodegenerative diseases with abnormal protein aggregates: The forgotten partner. Prog Neurobiol 2018; 169:24-54. [DOI: 10.1016/j.pneurobio.2018.07.004] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2018] [Revised: 07/24/2018] [Accepted: 07/27/2018] [Indexed: 12/31/2022]
|
8
|
Kovacs GG, Lee VM, Trojanowski JQ. Protein astrogliopathies in human neurodegenerative diseases and aging. Brain Pathol 2018; 27:675-690. [PMID: 28805003 DOI: 10.1111/bpa.12536] [Citation(s) in RCA: 61] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Accepted: 06/26/2017] [Indexed: 02/06/2023] Open
Abstract
Neurodegenerative diseases are characterized by progressive dysfunction and loss of neurons associated with depositions of pathologically altered proteins showing hierarchical involvement of brain regions. The role of astrocytes in the pathogenesis of neurodegenerative diseases is explored as contributors to neuronal degeneration or neuroprotection pathways, and also as potential mediators of the transcellular spreading of disease-associated proteins. Protein astrogliopathy (PAG), including deposition of amyloid-β, prion protein, tau, α-synuclein, and very rarely transactive response DNA-binding protein 43 (TDP-43) is not unprecedented or unusual in neurodegenerative diseases. Morphological characterization of PAG is considered, however, only for the neuropathological diagnosis and classification of tauopathies. Astrocytic tau pathology is seen in primary frontotemporal lobar degeneration (FTLD) associated with tau pathologies (FTLD-Tau), and also in the form of aging-related tau astrogliopathy (ARTAG). Importantly, ARTAG shares common features with primary FTLD-Tau as well as with the astroglial tau pathologies that are thought to be hallmarks of a brain injury-related tauopathy known as chronic traumatic encephalopathy (CTE). Supported by experimental observations, the morphological variability of PAG might reflect distinct pathogenic involvement of different astrocytic populations. PAG might indicate astrocytic contribution to spreading or clearance of disease-associated proteins, however, this might lead to astrocytic dysfunction and eventually contribute to the degeneration of neurons. Here, we review recent advances in understanding ARTAG and other related forms of PAG.
Collapse
Affiliation(s)
- Gabor G Kovacs
- Institute of Neurology, Medical University of Vienna, Vienna, Austria
| | - Virginia M Lee
- Center for Neurodegenerative Disease Research, Institute on Aging and Department of Pathology and Laboratory Medicine of the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - John Q Trojanowski
- Center for Neurodegenerative Disease Research, Institute on Aging and Department of Pathology and Laboratory Medicine of the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
9
|
Kovacs GG, Xie SX, Robinson JL, Lee EB, Smith DH, Schuck T, Lee VMY, Trojanowski JQ. Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain. Acta Neuropathol Commun 2018; 6:50. [PMID: 29891013 PMCID: PMC5996526 DOI: 10.1186/s40478-018-0552-y] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2018] [Accepted: 06/01/2018] [Indexed: 12/11/2022] Open
Abstract
Aging-related tau astrogliopathy (ARTAG) describes tau pathology in astrocytes in different locations and anatomical regions. In the present study we addressed the question of whether sequential distribution patterns can be recognized for ARTAG or astroglial tau pathologies in both primary FTLD-tauopathies and non-FTLD-tauopathy cases. By evaluating 687 postmortem brains with diverse disorders we identified ARTAG in 455. We evaluated frequencies and hierarchical clustering of anatomical involvement and used conditional probability and logistic regression to model the sequential distribution of ARTAG and astroglial tau pathologies across different brain regions. For subpial and white matter ARTAG we recognize three and two patterns, respectively, each with three stages initiated or ending in the amygdala. Subependymal ARTAG does not show a clear sequential pattern. For grey matter (GM) ARTAG we recognize four stages including a striatal pathway of spreading towards the cortex and/or amygdala, and the brainstem, and an amygdala pathway, which precedes the involvement of the striatum and/or cortex and proceeds towards the brainstem. GM ARTAG and astrocytic plaque pathology in corticobasal degeneration follows a predominantly frontal-parietal cortical to temporal-occipital cortical, to subcortical, to brainstem pathway (four stages). GM ARTAG and tufted astrocyte pathology in progressive supranuclear palsy shows a striatum to frontal-parietal cortical to temporal to occipital, to amygdala, and to brainstem sequence (four stages). In Pick’s disease cases with astroglial tau pathology an overlapping pattern with PSP can be appreciated. We conclude that tau-astrogliopathy type-specific sequential patterns cannot be simplified as neuron-based staging systems. The proposed cytopathological and hierarchical stages provide a conceptual approach to identify the initial steps of the pathogenesis of tau pathologies in ARTAG and primary FTLD-tauopathies.
Collapse
|
10
|
Borrego-Écija S, Grau-Rivera O, Colom-Cadena M, Molinuevo JL, Tolosa E, Sánchez-Valle R, Gelpi E. Tauopathy with Hippocampal 4-Repeat Tau Immunoreactive Spherical Inclusions in a Patient with PSP. Brain Pathol 2018. [PMID: 29516660 DOI: 10.1111/bpa.12506] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Affiliation(s)
- Sergi Borrego-Écija
- Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS, Barcelona, Spain.,Department of Neurology, Alzheimer and Cognitive Disorders Unit, Hospital Clinic de Barcelona, Spain
| | - Oriol Grau-Rivera
- Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS, Barcelona, Spain.,Department of Neurology, Alzheimer and Cognitive Disorders Unit, Hospital Clinic de Barcelona, Spain
| | - Martí Colom-Cadena
- Department of Neurology and Hospital de St Pau Research Center, Barcelona, Spain
| | - José Luis Molinuevo
- Department of Neurology, Alzheimer and Cognitive Disorders Unit, Hospital Clinic de Barcelona, Spain
| | - Eduard Tolosa
- Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS, Barcelona, Spain.,Department of Neurology, Movement Disorders Unit, Hospital Clinic de Barcelona, Barcelona, Spain
| | - Raquel Sánchez-Valle
- Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS, Barcelona, Spain.,Department of Neurology, Alzheimer and Cognitive Disorders Unit, Hospital Clinic de Barcelona, Spain
| | - Ellen Gelpi
- Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS, Barcelona, Spain
| |
Collapse
|